Li Guang, Xing Xiao-yan, Zhang Mei-shuang, Deng Xue-hong, Tang Shi-min, Zhao Na-na, Sun Gui-bo, Sun Xiao-bo
Yao Xue Xue Bao. 2016 Jul;51(7):1047-53.
Epigenetic is a hotspot of post-genomic era research, and epigenetic modification is a mechanism in the study of cardiovascular disease. Myocardial ischemia-reperfusion injury (MIRI) is one of the problems in the cardiovascular disease, and many experimental interventions are reported in the protection of the ischemic myocardium in experimental animals. However, with the exception of early reperfusion, none has been translated into clinical practice. There is an advantage of traditional Chinese medicine (TCM) in the regulation of epigenetic modification, and pathogenesis of myocardial ischemia-reperfusion injury. This review article is prepared to cover the research progress in the treatment of myocardial ischemia-reperfusion injury by TCM with a focus on epigenetic regulation. The epigenetic regulation is documented in TCM theory through a systematic review of the protecting drugs in the MIRI development guidelines.
表观遗传学是后基因组时代研究的热点,表观遗传修饰是心血管疾病研究中的一种机制。心肌缺血再灌注损伤(MIRI)是心血管疾病中的问题之一,在实验动物中保护缺血心肌方面有许多实验性干预措施被报道。然而,除了早期再灌注外,没有一项被转化为临床实践。中药在调节表观遗传修饰和心肌缺血再灌注损伤的发病机制方面具有优势。这篇综述文章旨在涵盖中药治疗心肌缺血再灌注损伤的研究进展,重点是表观遗传调控。通过对MIRI发展指南中的保护药物进行系统综述,在中医理论中记录了表观遗传调控。